Even a RAS‐mediated change in SBP could conceivably be an indirect consequence of chronic CB1 blockade because correction of hypercholesterolemia may downregulate AT1 receptor expression, which is correlated with plasma LDL levels in humans and animals (Nickenig et al. 1997). This evidence concerns the gene CNR1 and familial hypercholesterolemia.